|
**Overview**: ToRCH Antibodies Panel IgG IgM**Introduction**: The ToRCH Antibodies Panel IgG IgM is a diagnostic tool designed for congenital infection screening using serum samples. In India, ToRCH infections (Toxoplasma, Rubella, CMV, HSV) contribute significantly to congenital anomalies/miscarriages, with high seroprevalence (Toxoplasma ~10-20 percent, CMV ~80-90 percent) and primary infection risk in pregnancy. High morbidity from under-testing in rural/low-SES pregnant women, limited serology labs, delayed risk assessment leading to preventable fetal defects or stillbirth. Per obstetrics practices aligned with ICMR, FOGSI, and National Health Mission guidelines, the test employs immunoassay for Toxoplasma IgG/IgM over 1â€"2 days with high accuracy, valuable for initial screening in pregnancy (IgM for acute, IgG for past/immunity). This diagnostic falls under infectious disease screening and targets pregnant women in first trimester or with symptoms, addressing accurate detection to guide avidity/PCR or counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling focused Toxoplasma profiling and reducing congenital toxoplasmosis burden. Its serum-based approach ensures reliable IgG/IgM assessment.**Other Names**: Toxo Ab Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/immunology/clinical pathology, compliant with 2025 standards.**Historical Milestone**: Toxoplasma IgG/IgM standard in antenatal; in India, key in TORCH screening.**Purpose**: The test assesses 2 parameters including Toxoplasma IgG/IgM to guide congenital infection screening, detect acute/past exposure, inform intervention.**Test Parameters**: 1. Toxoplasma IgG, 2. Toxoplasma IgM.**Pretest Condition**: No fasting required; patients should be pregnant.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve antibody integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on gestational age, fever/rash.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of recent toxoplasmosis including fetal defects, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IgM + IgG indicates possible acute infection (high fetal risk), necessitating specialist input.**Specialist Consultation**: Obstetricians or infectious disease specialists should be consulted for management.**Additional Supporting Tests**: IgG avidity, PCR on amniotic fluid for confirmation.**Test Limitations**: IgM false positives possible; comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, TORCH Studies India 2023. |
